Vicapsys Life Sciences, Inc. (VICP) stock
VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)
Close on Oct 19, 2026Market cap $13.73MP/E –Yield –
Vicapsys Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Vicapsys Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2024 was $14.09K, down 7.7% year over year. For fiscal 2023 it was $15.27K, up 16.6% from the year before. The highest annual figure on record is $102.18K in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $15.27K | +16.6% |
| FY2022 | Dec 31, 2022 | $13.10K | -26.0% |
| FY2021 | Dec 31, 2021 | $17.70K | -82.7% |
| FY2020 | Dec 31, 2020 | $102.18K | +3.2% |
| FY2019 | Dec 31, 2019 | $98.98K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | $3.75K | +14.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.00K | +400.0% |
| Q1 FY2024 | Mar 31, 2024 | $344 | -96.6% |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $3.27K | +5.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $10.00K | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $3.10K | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $10.00K | +333.5% |
| Q4 FY2021 | Dec 31, 2021 | $10.46K | +28.6% |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $4.94K | – |
| Q1 FY2021 | Mar 31, 2021 | $2.31K | -97.5% |
| Q4 FY2020 | Dec 31, 2020 | $8.13K | -91.8% |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $94.05K | – |
| Q3 FY2019 | Sep 30, 2019 | $98.98K | – |
See a number that looks wrong?